TMDX — TransMedics Income Statement
0.000.00%
- $4.96bn
- $5.12bn
- $241.62m
- 37
- 6
- 100
- 45
Annual income statement for TransMedics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 28th | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 52 W | 53 W | 52 W | 52 W | 52 W |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 23.6 | 25.6 | 30.3 | 93.5 | 242 |
Cost of Revenue | |||||
Gross Profit | 13.9 | 16.6 | 21.2 | 65.3 | 154 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 53.2 | 52 | 69.7 | 124 | 270 |
Operating Profit | -29.6 | -26.4 | -39.4 | -30.8 | -28.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -33.5 | -28.7 | -44.2 | -36.2 | -26.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -33.5 | -28.7 | -44.2 | -36.2 | -25 |
Net Income Before Extraordinary Items | |||||
Net Income | -33.5 | -28.7 | -44.2 | -36.2 | -25 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -33.5 | -28.7 | -44.2 | -36.2 | -25 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.36 | -1.16 | -1.6 | -1.24 | 0.107 |